



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ashkenazi et al. Docket No.: 39780-1618P2C80  
Serial No.: 09/909,320 Group Art Unit: 1647  
Filing Date: July 18, 2001 Examiner: Hamud, Fozia M.  
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME**  
Express Mail Label No.: EL 993 689 491 US  
Mailing Date: October 20, 2004

### INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The Applicant notes that prosecution on the merits was re-opened by the Examiner in the Office action dated April 20, 2004.

Listed on an attached Form PTO-1449 is information known to applicant(s). Each reference listed has been cited in related patent application US Serial No. 09/903,640; Our Ref. No. 39780-1618P2C48 and/or US Serial No. 09/903,925; Our Ref. No. 39780-1618P2C49. Therefore, a copy of each reference is not provided. The applicant would be happy to provide a copy upon request. Applicants propose these documents for consideration for completeness in cross-citation within the related applications. Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. The Examiner is requested to initial and return form PTO-1449 in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

- (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  
-- OR --
- (2) It is being filed within 3 months of entry of a national stage  
-- OR --
- (3) It is being filed before the mail date of the first Office Action on the merits  
-- OR --

10/26/2004 AMONDAF1 00000088-081641 09909320

02-FEB-1253 <980.00 DA

10/26/2004 AMONDAF1 00000088 09909320  
01-FEB-1253 180.00 DA  
01-FEB-1253 180.00 DA

- (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- a certification as specified in §1.97(e) is provided below; **or**
- a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; **and**
  - B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**
  - C. a fee of \$180.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 39780-1618P2C80).

Respectfully submitted,

By: Daphne Reddy  
Daphne Reddy  
Reg. No. 53,507

Dated: October 20, 2004

Doc # 2032898

**HELLER EHRLMAN WHITE & MCAULIFFE LLP**  
**Customer No. 09157/35489**  
275 Middlefield Road  
Menlo Park, CA 94025-3506  
Telephone: (650) 324-7000  
Facsimile: (650) 324-0638



INFORMATION DISCLOSURE STATEMENT  PTO-1449		ATTY. DOCKET NO.:		SERIAL NO.:			
		39780-1618P2C80		09/909,320			
		APPLICANT : Avi Ashkenazi, et al.					
FILING DATE: July 18, 2001		GROUP: 1647					
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	5,821,337	10/1998	Carter et al.				
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 98/36054	8/1998	PCT (Amrad Operations)			<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	Atwood, "The babel of bioinformatics", 2000, SCIENCE, Vol. 290, pp 471-473						
	Berendsen, H. "A Glimpse of the Holy Grail?", SCIENCE, 282, pp 642-643, 1998						
	Galperin et al, "Who's your neighbor?, New Computational approaches for functional genomics", NATURE BIOTECHNOLOGY, Vol. 18, pp 609-613, 2002						
	Haynes et al, "Proteome analysis: Biological assay or data archive?" Electrophoresis, Vol. 19, pages 1862-1871, 1998.						
	Konopka et al, "Variable expression of the translocated c-abl oncogene in philadelphia-chromosome-positive B-lymphoid cell lines from chronic myelogenous leukemia patients" Proc. Natl. Acad. Sci. USA, Vol. 83, pps 4049-4052, June 1986.						
EXAMINER		DATE CONSIDERED					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.